Disclosed is a compound of formula (I) e.g. 3-[7-(5-{ 3-chloro-4-[(1-methylethyl)oxy]phenyl} -1,2,4-oxadiazol-3-yl)-2,3,4,5-tetrahydro-1H-2-benzazepin-1-yl]propanamide or a pharmaceutically acceptable salt thereof wherein for use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and noninsulin dependant diabetes.
